Lifang Pharmaceutical hired Wang Qing as the company's deputy general manager In the first half of the year, the company's net profit was 83.5844 million

On August 16, 2020, Lifang Pharmaceutical (003020) held the twelfth meeting of the fourth board of directors on August 14, 2021, and deliberated and passed the "Proposal on Electing Wang Qing as a Director of the Fourth Board of Directors of the Company" and "Proposal on Appointing Wang Qing as the Deputy General Manager of the Company". The Board of Directors agreed to elect Wang Qing as a non-independent director of the fourth board of directors, and the term of office is from the date of deliberation and approval of the company's shareholders' general meeting to the expiration date of the fourth board of directors of the company, and the proposal to elect Wang Qing as a non-independent director needs to be submitted to the company's third extraordinary general meeting of shareholders in 2021 for deliberation and approval. Agreed to appoint Wang Qing as the deputy general manager of the company, and the term of office is from the date of deliberation and approval of the board of directors to the expiration date of the fourth board of directors of the company.

The independent directors of the Company have expressed a concurring independent opinion on the election of directors and the appointment of deputy general managers. After the election of Wang Qing as a non-independent director, the fourth board of directors of the company consists of 7 directors, including 3 independent directors, and the number of directors who are concurrently senior management personnel of the company on the board of directors and the directors served by employee representatives does not exceed one-half of the total number of directors of the company.

Wang Qing: Chinese nationality, no right of permanent residence abroad, born in November 1967, graduate degree, chief pharmacist. He once served as a quality supervisor and engineer of the preparation workshop and quality supervision department of Hefei Pharmaceutical Factory, the manager of the quality management department of Anhui Great Eastern Pharmaceutical Co., Ltd., the manager of the production technology department of Hefei Lifang Pharmaceutical Co., Ltd., the deputy general manager of the main plant, the executive deputy general manager and general manager of Hefei Chengzhi Biopharmaceutical Co., Ltd., the current general manager of the headquarters of Hefei Lifang Pharmaceutical Co., Ltd., the executive director of Hefei Chengzhi Biopharmaceutical Co., Ltd., and the executive director of Jinzhai Lifang Pharmaceutical Co., Ltd. Mainly responsible for production technology, quality management and other related work, has a wealth of practical experience in the implementation of pharmaceutical production quality management system and GMP management.

The company's 2021 semi-annual report shows that the company's net profit attributable to shareholders of listed companies in the first half of 2021 was 83,584,376.44 yuan, an increase of 26.55% over the same period last year.

According to the data of the digging shell network, the main business of Lifang Pharmaceutical includes the pharmaceutical industry and pharmaceutical business. In the pharmaceutical industry, it mainly includes the research and development, production and sales of pharmaceutical preparations and APIs, and the main industrial products involve cardiovascular drugs, digestive system drugs, skin external drugs and other fields. Pharmaceutical business includes the wholesale and retail of drugs and medical devices.

Source link: http://www.szse.cn/disclosure/listed/bulletinDetail/index.html?e6b063f9-7d29-4c64-ae38-c2d96e88c5ff

This article originated from the digging shell network